New once‐daily, highly effective rescue triple therapy after multiple <i>Helicobacter pylori</i> treatment failures: a pilot study

Coelho, Luiz Gonzaga Vaz; Moretzsohn, Luciana Dias; Vieira, Washington L.; Gallo, M A; Passos, M. C. F.; Cindr, Josef; Cerqueira, Maria Clara Salim; Vitiello, L; Ribeiro, Marcelo Lima; Mendonça, Sérgio; Pedrazzoli-Júnior, José; Castro, Lúcia Porto Fonseca de

doi:10.1111/j.1365-2036.2005.02370.x

Cited by 55 publications

(50 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Case reports of hepatotoxicity have also been published [Spahr et al 2001]. Myelosuppression has been noted in patients taking rifabutin [Coelho et al 2005]. It had been hoped that the concurrent administration of probiotics would lessen the side-effect profile of triple therapy; however, this may also increase the complexity of the treatment regimen.…”

Section: Side Effectsmentioning

confidence: 99%

Review: Improving compliance with Helicobacter pylori eradication therapy: when and how?

O’Connor

Taneike

O’Moráin

2009

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Compliance with therapy is the single most important factor in Helicobacter pylori (H. pylori) eradication. Poorer levels of compliance with therapy are associated with significantly lower levels of eradication. Numerous factors can contribute to achieving good levels of compliance. These include the complexity and duration of treatment. It is also important that the physician is motivated to ensure eradication is confirmed and the patient is sufficiently informed to empower him or her to achieve high levels of compliance. Compliance is also contingent on medication regimes that are simple, safe, tolerable and efficacious. The opportunity to improve compliance exists at every point of contact between the patient and the medical services. Experts and opinion leaders in the field can play a role by ensuring that physicians are educated and motivated enough to encourage and support compliance with H. pylori eradication therapy. Both patients and physicians need to be aware of the importance of the bacterium in causing disease. The importance of the doctorpatient relationship is paramount. Pragmatic strategies that may be of assistance may come in the form of polypills, combined Blister Packs, adjuvant therapies and modified release compounds. Colleagues such as pharmacists and nurse specialists can also play an important role and should be actively engaged. Structured aftercare and follow up offers the best chance for ensuring compliance and subsequent eradication of the H. pylori pathogen.

show abstract

Section: Side Effectsmentioning

confidence: 99%

Review: Improving compliance with Helicobacter pylori eradication therapy: when and how?

O’Connor

Taneike

O’Moráin

2009

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…A recomendação do emprego da associação de levofloxacina, furazolidona e IBP em dose única diária baseou-se em estudo piloto nacional com excelentes resultados iniciais (4) . O Consenso recomendou também, a realização de estudo multicêntrico nacional para validação nacional dos esquemas aqui sugeridos.…”

Section: Comentáriosunclassified

II Consenso Brasileiro sobre Helicobacter pylori

Coelho

Zaterka

2005

Arq. Gastroenterol.

View full text Add to dashboard Cite

INTRODUÇÃODesde sua identificação por MARSHALL e WARREN (13) , em 1982, O Helicobacter pylori (HP) rapidamente se tornou alvo de incontáveis estudos microbiológicos, histológicos, epidemiológicos, imunológicos, ecológicos e clínicos, entre outros. Conseqüentemente, em curto período de tempo, os avanços do conhecimento na área puderam ser utilizados, de forma revolucionária, na prática médica diária de clínicos e gastroenterologistas. O alcance desta descoberta pode ser avaliado pelo resultado de inquérito recente entre gastroenterologistas, onde tal descoberta foi considerada a mais importante da especialidade no último século (8) .Com o objetivo de orientar os médicos nas várias questões relacionadas ao manuseio da infecção pelo HP, diferentes reuniões de consenso têm sido realizadas em todo o mundo (1,5,10,12,15,23) . No Brasil, em 1995, durante o Congresso Panamericano de Enfermedades Digestivas, realizado em Belo Horizonte, MG, foi realizado o "Consenso Nacional sobre H. pylori e afecções associadas" (2) .A

show abstract

“…Although widely used in Brazil there are no validation studies among us. National studies employing a standard dose of proton pump inhibitor, and furazolidone 400 mg and levofloxacin 500 mg, taken once daily for 10 days, or a standard dose of proton pump inhibitor associated with furazolidone 200 mg and levofloxacin 250 mg, administered twice daily for 7 days, have obtained eradication rates close to 80% (30,44,181) .…”

Section: Statement 30mentioning

confidence: 99%

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Coelho

Maguinilk

Zaterka³

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

Significant progress has been obtained since the Second Brazilian Consensus Conference on Helicobacter pylori Infection held in 2004, in São Paulo, SP, Brazil, and justify a third meeting to establish updated guidelines on the current management of H. pylori infection. The Third Brazilian Consensus Conference on H pylori Infection was organized by the Brazilian Nucleus for the Study of Helicobacter, a Department of the Brazilian Federation of Gastroenterology and took place on April 12-15, 2011, in Bento Gonçalves, RS, Brazil. Thirty-one delegates coming from the five Brazilian regions and one international guest, including gastroenterologists, pathologists, epidemiologists, and pediatricians undertook the meeting. The participants were allocated in one of the five main topics of the meeting: H pylori, functional dyspepsia and diagnosis; H pylori and gastric cancer; H pylori and other associated disorders; H pylori treatment and retreatment; and, epidemiology of H pylori infection in Brazil. The results of each subgroup were submitted to a final consensus voting to all participants. Relevant data were presented, and the quality of evidence, strength of recommendation, and level of consensus were graded. Seventy per cent and more votes were considered as acceptance for the final statement. This article presents the main recommendations and conclusions to guide Brazilian doctors involved in the management of H pylori infection.

show abstract

New once‐daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study

Cited by 55 publications

References 27 publications

Review: Improving compliance with Helicobacter pylori eradication therapy: when and how?

Review: Improving compliance with Helicobacter pylori eradication therapy: when and how?

II Consenso Brasileiro sobre Helicobacter pylori

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Contact Info

Product

Resources

About